Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 9468087, 15 pages
http://dx.doi.org/10.1155/2016/9468087
Research Article

Identification of “Multiple Components-Multiple Targets-Multiple Pathways” Associated with Naoxintong Capsule in the Treatment of Heart Diseases Using UPLC/Q-TOF-MS and Network Pharmacology

1State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
2College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

Received 30 January 2016; Accepted 2 March 2016

Academic Editor: Carmen Mannucci

Copyright © 2016 Xianghui Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Su, Y. Li, B. Lv et al., “Clinical study on Naoxintong capsule for stroke recovery of Qi-deficiency and blood-stasis syndrome,” Zhongguo Zhongyao Zazhi, vol. 36, no. 11, pp. 1530–1533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L.-X. Li, L. Chen, and H.-J. Zhao, “Effect of naoxintong capsule on the vascular endothelial function and the infarct size of patients with acute myocardial infarction,” Chinese Journal of Integrated Traditional And Western Medicine, vol. 31, no. 12, pp. 1615–1618, 2011. View at Google Scholar · View at Scopus
  3. S.-R. Li, T.-H. Wang, and B.-J. Zhang, “Effects of naoxintong capsule on the inflammation and prognosis in borderline lesion coronary heart disease patients,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 5, pp. 607–611, 2012. View at Google Scholar · View at Scopus
  4. J. Zhao, H. Zhu, S. Wang et al., “Naoxintong protects against atherosclerosis through lipid-lowering and inhibiting maturation of dendritic cells in LDL receptor knockout mice fed a high-fat diet,” Current Pharmaceutical Design, vol. 19, no. 33, pp. 5891–5896, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. X.-N. Zhong, H.-H. Wang, Z.-Q. Lu et al., “Effects of naoxintong on atherosclerosis and inducible nitric oxide synthase expression in atherosclerotic rabbit,” Chinese Medical Journal, vol. 126, no. 6, pp. 1166–1170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Zhang, B. Huang, Y. Zhao et al., “BNC protects H9c2 cardiomyoblasts from H2O2-induced oxidative injury through ERK1/2 signaling pathway,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 802784, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Liu, Y. Liu, L. Wang et al., “The disease burden of cardiovascular and circulatory diseases in China, 1990 and 2010,” Chinese Journal of Preventive Medicine, vol. 49, no. 4, pp. 315–320, 2015. View at Google Scholar · View at Scopus
  8. C.-M. Lin, J.-H. Chiu, I.-H. Wu, B.-W. Wang, C.-M. Pan, and Y.-H. Chen, “Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1α,” Journal of Nutritional Biochemistry, vol. 21, no. 7, pp. 627–633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-L. Tang, J.-X. Liu, P. Li et al., “Protective effect of succinic acid on primary cardiomyocyte hypoxia/reoxygenation injury,” China Journal of Chinese Materia Medica, vol. 38, no. 21, pp. 3742–3746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. W.-D. Zhang, H. Chen, C. Zhang, R.-H. Liu, H.-L. Li, and H.-Z. Chen, “Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro,” Planta Medica, vol. 72, no. 1, pp. 4–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Wang, D. A. Liem, T. M. Vondriska et al., “Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 288, no. 3, pp. H1290–H1295, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Hausenloy, M. R. Duchen, and D. M. Yellon, “Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury,” Cardiovascular Research, vol. 60, no. 3, pp. 617–625, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Fu, H. Huang, J. Liu, R. Pi, J. Chen, and P. Liu, “Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 213–221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. W. Russell, D. J. Munroe, E. Bric et al., “A 500-kb physical map and contig from the Harvey ras-1 gene to the 11p telomere,” Genomics, vol. 35, no. 2, pp. 353–360, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Burgoyne, D. J. Haeussler, V. Kumar et al., “Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis,” The FASEB Journal, vol. 26, no. 2, pp. 832–841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. E. D. Martin, G. Felice De Nicola, and M. S. Marber, “New therapeutic targets in cardiology: P38 alpha mitogen-activated protein kinase for ischemic heart disease,” Circulation, vol. 126, no. 3, pp. 357–368, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. van Rooij, P. A. Doevendans, C. C. De Theije, F. A. Babiker, J. D. Molkentin, and L. J. de Windt, “Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy,” The Journal of Biological Chemistry, vol. 277, no. 50, pp. 48617–48626, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rinne, N. Kapur, J. D. Molkentin et al., “Isoform- and tissue-specific regulation of the Ca2+-sensitive transcription factor NFAT in cardiac myocytes and heart failure,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 6, pp. H2001–H2009, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Rao, C. Luo, and P. G. Hogan, “Transcription factors of the NFAT family: regulation and function,” Annual Review of Immunology, vol. 15, pp. 707–747, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Papademetriou, “From hypertension to heart failure,” Journal of Clinical Hypertension, vol. 6, no. 10, supplement 2, pp. 14–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. I. G. Schulman, “Nuclear receptors as drug targets for metabolic disease,” Advanced Drug Delivery Reviews, vol. 62, no. 13, pp. 1307–1315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M.-W. Huang, H. Wang, W.-J. Zhong, X.-Y. Wu, and H. Chen, “Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi,” Journal of Chinese Integrative Medicine, vol. 9, no. 1, pp. 38–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. Z.-H. Liu and X.-B. Sun, “Network pharmacology: new opportunity for the modernization of traditional Chinese medicine,” Acta Pharmaceutica Sinica, vol. 47, no. 6, pp. 696–703, 2012. View at Google Scholar · View at Scopus
  24. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at Publisher · View at Google Scholar · View at Scopus